Literature DB >> 21965832

Handling and reporting of nephrectomy specimens for adult renal tumours: a survey by the European Network of Uropathology.

Ferran Algaba1, Brett Delahunt, Daniel M Berney, Philippe Camparo, Eva Compérat, David Griffiths, Glen Kristiansen, Antonio Lopez-Beltran, Guido Martignoni, Holger Moch, Rodolfo Montironi, Murali Varma, Lars Egevad.   

Abstract

AIM: To collect information on current practices of European pathologists for the handling and reporting of nephrectomy specimens with renal tumours. METHODS AND
RESULTS: A questionnaire was circulated to the members of the European Network of Uropathology, which consists of 343 pathologists in 15 European countries. Replies were received from 48% of members. These replies indicated that nephrectomy specimens are most often received in formalin. Lymph nodes are found in less than 5% of nephrectomy specimens. All respondents give an objective measure of tumour size, most commonly in three diameters. The most common method to search for capsule penetration is to slice tissue outside the tumour perpendicularly into the tumour. The most common sampling algorithm from tumours greater than 2 cm is one section for every centimetre of maximum tumour diameter. Most respondents use the 2004 WHO renal tumour classification although only slightly over half consider small papillary tumours malignant if the diameter is greater than 5 mm. The Fuhrman grading system is widely used. Almost all use immunohistochemistry for histological typing in some cases, while only 7% always use it. The most utilised special stains are CK7 (95%), CD10 (93%), vimentin (86%), HMB45 (68%), c-kit (61%) and Hale's colloidal iron (52%). Only 18% use other ancillary techniques for diagnosis in difficult cases.
CONCLUSIONS: While most pathologists appear to follow published guidelines for reporting renal carcinoma, there is still a need for the development of consensus and further standardisation of practice for contentious areas of specimen handling and reporting.

Entities:  

Mesh:

Year:  2011        PMID: 21965832     DOI: 10.1136/jclinpath-2011-200339

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  9 in total

1.  Large (>3.8 cm) clear cell renal cell carcinomas are morphologically and immunohistochemically heterogeneous.

Authors:  Laura Zaldumbide; Asier Erramuzpe; Rosa Guarch; Jesús M Cortés; José I López
Journal:  Virchows Arch       Date:  2014-11-05       Impact factor: 4.064

2.  [Vancouver classification of renal tumors: Recommendations of the 2012 consensus conference of the International Society of Urological Pathology (ISUP)].

Authors:  G Kristiansen; B Delahunt; J R Srigley; C Lüders; J-M Lunkenheimer; H Gevensleben; T Thiesler; R Montironi; L Egevad
Journal:  Pathologe       Date:  2015-05       Impact factor: 1.011

Review 3.  [Renal cancer biomarkers. What is justified?].

Authors:  H Moch
Journal:  Pathologe       Date:  2012-11       Impact factor: 1.011

Review 4.  The Nephrologist's Tumor: Basic Biology and Management of Renal Cell Carcinoma.

Authors:  Susie L Hu; Anthony Chang; Mark A Perazella; Mark D Okusa; Edgar A Jaimes; Robert H Weiss
Journal:  J Am Soc Nephrol       Date:  2016-03-09       Impact factor: 10.121

Review 5.  Renal cell carcinoma: new insights and challenges for a clinician scientist.

Authors:  Roman Shingarev; Edgar A Jaimes
Journal:  Am J Physiol Renal Physiol       Date:  2017-04-05

6.  Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study.

Authors:  Matteo Brunelli; Guido Martignoni; Giorgio Malpeli; Alessandro Volpe; Luca Cima; Maria Rosaria Raspollini; Mattia Barbareschi; Alessandro Tafuri; Giulia Masi; Luisa Barzon; Serena Ammendola; Manuela Villanova; Maria Angela Cerruto; Michele Milella; Sebastiano Buti; Melissa Bersanelli; Giuseppe Fornarini; Sara Elena Rebuzzi; Valerio Gaetano Vellone; Gabriele Gaggero; Giuseppe Procopio; Elena Verzoni; Sergio Bracarda; Martina Fanelli; Roberto Sabbatini; Rodolfo Passalacqua; Bruno Perrucci; Maria Olga Giganti; Maddalena Donini; Stefano Panni; Marcello Tucci; Veronica Prati; Cinzia Ortega; Anna Caliò; Albino Eccher; Filippo Alongi; Giovanni Pappagallo; Roberto Iacovelli; Alessandra Mosca; Paolo Umari; Ilaria Montagnani; Stefano Gobbo; Francesco Atzori; Enrico Munari; Marco Maruzzo; Umberto Basso; Francesco Pierconti; Carlo Patriarca; Piergiuseppe Colombo; Alberto Lapini; Giario Conti; Roberto Salvioni; Enrico Bollito; Andrea Cossarizza; Francesco Massari; Mimma Rizzo; Renato Franco; Federica Zito-Marino; Yoseba Aberasturi Plata; Francesca Galuppini; Marta Sbaraglia; Matteo Fassan; Angelo Paolo Dei Tos; Maurizio Colecchia; Holger Moch; Maurizio Scaltriti; Camillo Porta; Brett Delahunt; Gianluca Giannarini; Roberto Bortolus; Pasquale Rescigno; Giuseppe Luigi Banna; Alessio Signori; Miguel Angel Llaja Obispo; Roberto Perris; Alessandro Antonelli
Journal:  J Pers Med       Date:  2022-04-30

Review 7.  Pathological Bases and Clinical Impact of Intratumor Heterogeneity in Clear Cell Renal Cell Carcinoma.

Authors:  José I López; Javier C Angulo
Journal:  Curr Urol Rep       Date:  2018-01-27       Impact factor: 3.092

8.  Classic Chromophobe Renal Cell Carcinoma Incur a Larger Number of Chromosomal Losses Than Seen in the Eosinophilic Subtype.

Authors:  Riuko Ohashi; Peter Schraml; Silvia Angori; Aashil A Batavia; Niels J Rupp; Chisato Ohe; Yoshiro Otsuki; Takashi Kawasaki; Hiroshi Kobayashi; Kazuhiro Kobayashi; Tatsuhiko Miyazaki; Hiroyuki Shibuya; Hiroyuki Usuda; Hajime Umezu; Fumiyoshi Fujishima; Bungo Furusato; Mitsumasa Osakabe; Tamotsu Sugai; Naoto Kuroda; Toyonori Tsuzuki; Yoji Nagashima; Yoichi Ajioka; Holger Moch
Journal:  Cancers (Basel)       Date:  2019-10-03       Impact factor: 6.639

9.  Snail heterogeneity in clear cell renal cell carcinoma.

Authors:  Laura Zaldumbide; Asier Erramuzpe; Rosa Guarch; Rafael Pulido; Jesús M Cortés; José I López
Journal:  BMC Cancer       Date:  2016-03-08       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.